High-Grade Serous Ovarian Cancers Derived − Transformation to Promote Formation of Fallopian Tube Cyclin E 1 Deregulation Occurs Early in Secretory Cell
暂无分享,去创建一个
D. Etemadmoghadam | D. Bowtell | R. Drapkin | A. Ligon | M. Hirsch | Joyce F. Liu | N. Vena | A. Karst | P. M. Jones | Alison M. Karst | Natalie Vena
[1] I. Shih,et al. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. , 2014, Annual review of pathology.
[2] R. Drapkin,et al. Coming into focus: the nonovarian origins of ovarian cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] T. Helleday,et al. Increased replication initiation and conflicts with transcription underlie Cyclin E-induced replication stress , 2013, Oncogene.
[4] Maya Raghunandan,et al. FANCD2 regulates BLM complex functions independently of FANCI to promote replication fork recovery , 2013, Nucleic acids research.
[5] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[6] I. Shih,et al. Rsf‐1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development , 2013, The Journal of pathology.
[7] R. Drapkin,et al. Primary culture and immortalization of human fallopian tube secretory epithelial cells , 2012, Nature Protocols.
[8] Hong Wu,et al. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. , 2012, Cancer cell.
[9] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[10] G. Mills,et al. LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients , 2012, PLoS genetics.
[11] Joe W. Gray,et al. Genome Wide DNA Copy Number Analysis of Serous Type Ovarian Carcinomas Identifies Genetic Markers Predictive of Clinical Outcome , 2012, PloS one.
[12] M. Rosner,et al. An integrated view of cyclin E function and regulation , 2012, Cell cycle.
[13] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[14] B. Kerem,et al. Nucleotide Deficiency Promotes Genomic Instability in Early Stages of Cancer Development , 2011, Cell.
[15] R. Drapkin,et al. Modeling high-grade serous ovarian carcinogenesis from the fallopian tube , 2011, Proceedings of the National Academy of Sciences.
[16] D. Ginsberg,et al. miR-15 and miR-16 Are Direct Transcriptional Targets of E2F1 that Limit E2F-Induced Proliferation by Targeting Cyclin E , 2011, Molecular Cancer Research.
[17] Kylie L. Gorringe,et al. Amplicon-Dependent CCNE1 Expression Is Critical for Clonogenic Survival after Cisplatin Treatment and Is Correlated with 20q11 Gain in Ovarian Cancer , 2010, PloS one.
[18] David D. L. Bowtell,et al. The genesis and evolution of high-grade serous ovarian cancer , 2010, Nature Reviews Cancer.
[19] Kylie L. Gorringe,et al. Copy Number Analysis Identifies Novel Interactions Between Genomic Loci in Ovarian Cancer , 2010, PloS one.
[20] G. Ning,et al. A Pathologist's Road Map to Benign, Precancerous, and Malignant Intraepithelial Proliferations in the Fallopian Tube , 2010, Advances in anatomic pathology.
[21] A. Składanowski,et al. H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy , 2010, Journal of nucleic acids.
[22] K. Hunt,et al. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. , 2010, Cancer research.
[23] Kentaro Nakayama,et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer , 2010, Cancer.
[24] I. Shih,et al. Serous tubal intraepithelial carcinoma upregulates markers associated with high-grade serous carcinomas including Rsf-1 (HBXAP), cyclin E and fatty acid synthase , 2010, Modern Pathology.
[25] M. Hirsch,et al. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. , 2009, Gynecologic oncology.
[26] Varda Rotter,et al. When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.
[27] R. Drapkin,et al. Ovarian Cancer Pathogenesis: A Model in Evolution , 2009, Journal of oncology.
[28] Joshy George,et al. Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.
[29] Jesse D. Martinez,et al. Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells. , 2008, Neoplasia.
[30] R. Drapkin,et al. Serous Carcinogenesis in the Fallopian Tube: A Descriptive Classification , 2008, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[31] B. Clurman,et al. p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability , 2007, Oncogene.
[32] D. Albertson,et al. DNA profiling of primary serous ovarian and Fallopian tube carcinomas with array comparative genomic hybridization and multiplex ligation‐dependent probe amplification , 2007, The Journal of pathology.
[33] E. Dmitrovsky,et al. Transgenic cyclin E triggers dysplasia and multiple pulmonary adenocarcinomas , 2007, Proceedings of the National Academy of Sciences.
[34] R. Berkowitz,et al. Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship , 2007, The American journal of surgical pathology.
[35] J. Garber,et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube , 2007 .
[36] S. Reed,et al. Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland , 2006, Oncogene.
[37] Dimitris Kletsas,et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints , 2006, Nature.
[38] Christopher P Crum,et al. The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome , 2006, The American journal of surgical pathology.
[39] James M. Roberts,et al. A mouse model for cyclin E-dependent genetic instability and tumorigenesis. , 2005, Cancer cell.
[40] Ajay N. Jain,et al. Genome-wide-array-based comparative genomic hybridization reveals genetic homogeneity and frequent copy number increases encompassing CCNE1 in Fallopian tube carcinoma , 2003, Oncogene.
[41] B. Stewart,et al. World Cancer Report , 2003 .
[42] B. Clurman,et al. p53 and p21 Form an Inducible Barrier that Protects Cells against Cyclin E-cdk2 Deregulation , 2002, Current Biology.
[43] P. V. van Diest,et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer , 2001, The Journal of pathology.
[44] Rochelle L. Garcia,et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. , 2001, Gynecologic oncology.
[45] S. Reed,et al. Deregulated cyclin E induces chromosome instability , 1999, Nature.
[46] L. Johnson,et al. Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity* , 1999, The Journal of Biological Chemistry.
[47] W. Hahn,et al. Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[48] D. Bortner,et al. Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human cyclin E , 1997, Molecular and cellular biology.
[49] Melanie M. Choe,et al. The comet assay: a method to measure DNA damage in individual cells , 2006, Nature Protocols.